Latest Period
Q4 2025
Security Snapshot
Immunovant, Inc. - Common Stock, par value $0.0001 per share (IMVT) Institutional Ownership
CUSIP: 45258J102
13F Institutional Holders and Ownership History from Q4 2019 to Q1 2026
Institutions Reporting
194
Shares (Excl. Options)
108,607,774
Price
$25.42
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- IMVT on Nasdaq
- Shares outstanding
- 202,731,676
- Price per share
- $24.89
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 108,607,774
- Total reported value
- $2,761,164,222
- % of total 13F portfolios
- 0.01%
- Share change
- +13,570,331
- Value change
- +$365,946,432
- Number of holders
- 194
- Price from insider filings
- $24.89
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- IMVT - Immunovant, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 45258J102.
- 194 institutions reported positions in Q4 2025.
- 3 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 194 to 76 between Q4 2025 and Q1 2026.
- Reported value moved from $2,761,164,222 to $398,019,367.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 194 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 45258J102?
CUSIP 45258J102 identifies IMVT - Immunovant, Inc. - Common Stock, par value $0.0001 per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 45258J102:
Significant Owners of Immunovant, Inc. - Common Stock, par value $0.0001 per share (IMVT) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Roivant Sciences Ltd. | 56% | -1.8% | $2,812,776,314 | +$413,666,650 | 113,327,007 | +17% | Roivant Sciences Ltd. | 12 Dec 2025 |
| FMR LLC | 8.4% | -17% | $237,440,423 | -$37,858,433 | 14,729,555 | -14% | FMR LLC | 30 Sep 2025 |
| Deep Track Capital, LP | 5.6% | $144,590,000 | 9,500,000 | Deep Track Capital, LP | 19 Mar 2025 |
As of 31 Dec 2025, 194 institutional investors reported holding 108,607,774 shares of Immunovant, Inc. - Common Stock, par value $0.0001 per share (IMVT). This represents 54% of the company’s total 202,731,676 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Immunovant, Inc. - Common Stock, par value $0.0001 per share (IMVT) together control 47% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 8.4% | 16,990,754 | +15% | 0.02% | $431,904,967 |
| Deep Track Capital, LP | 5.7% | 11,526,971 | +18% | 6.7% | $293,015,603 |
| VANGUARD GROUP INC | 3.8% | 7,779,314 | +14% | 0% | $197,750,162 |
| BlackRock, Inc. | 3% | 6,058,216 | +5.6% | 0% | $153,999,851 |
| ARMISTICE CAPITAL, LLC | 2.8% | 5,747,155 | -1.5% | 3.6% | $146,092,680 |
| BAKER BROS. ADVISORS LP | 2.7% | 5,457,881 | 0% | 0.81% | $138,739,335 |
| T. Rowe Price Investment Management, Inc. | 2.5% | 5,060,399 | -2% | 0.08% | $128,636,000 |
| MORGAN STANLEY | 2.4% | 4,846,384 | +147% | 0.01% | $123,195,110 |
| STATE STREET CORP | 1.9% | 3,786,926 | +31% | 0% | $96,263,659 |
| RTW INVESTMENTS, LP | 1.6% | 3,177,850 | 0.81% | $80,780,947 | |
| Two Seas Capital LP | 1.4% | 2,866,962 | +3.8% | 4.3% | $72,878,174 |
| Alpine Global Management, LLC | 1.3% | 2,626,692 | -4.6% | 16% | $66,770,511 |
| ADAR1 Capital Management, LLC | 1.2% | 2,480,968 | +11% | 4.7% | $63,066,207 |
| Point72 Asset Management, L.P. | 0.99% | 2,000,000 | -42% | 0.08% | $50,840,000 |
| PERCEPTIVE ADVISORS LLC | 0.98% | 1,994,890 | +26% | 0.93% | $50,710,104 |
| Woodline Partners LP | 0.97% | 1,975,869 | +32% | 0.19% | $50,226,590 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.92% | 1,857,532 | +3.1% | 0% | $47,226,549 |
| TCG Crossover Management, LLC | 0.82% | 1,660,933 | 1.4% | $42,220,917 | |
| Logos Global Management LP | 0.68% | 1,375,000 | +400% | 2.3% | $34,952,500 |
| GOLDMAN SACHS GROUP INC | 0.64% | 1,296,008 | -13% | 0% | $32,944,523 |
| Aberdeen Group plc | 0.58% | 1,184,122 | +21% | 0.05% | $30,100,381 |
| Soleus Capital Management, L.P. | 0.55% | 1,110,000 | 1.2% | $28,216,200 | |
| PRICE T ROWE ASSOCIATES INC /MD/ | 0.44% | 893,056 | +337% | 0% | $22,703,000 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 0.43% | 863,000 | +151% | 0.03% | $21,937,460 |
| GREAT POINT PARTNERS LLC | 0.37% | 750,000 | +50% | 6.2% | $19,065,000 |
Institutional Holders of Immunovant, Inc. - Common Stock, par value $0.0001 per share (IMVT) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 16,023,311 | $398,019,367 | +$61,546,913 | $24.84 | 76 |
| 2025 Q4 | 108,607,774 | $2,761,164,222 | +$365,946,432 | $25.42 | 194 |
| 2025 Q3 | 95,145,471 | $1,533,747,121 | -$22,890,328 | $16.12 | 183 |
| 2025 Q2 | 96,203,927 | $1,539,273,430 | +$25,954,256 | $16.00 | 167 |
| 2025 Q1 | 94,088,777 | $1,608,317,726 | +$221,642,111 | $17.09 | 191 |
| 2024 Q4 | 80,137,358 | $1,984,988,003 | -$10,994,227 | $24.77 | 186 |
| 2024 Q3 | 79,205,377 | $2,259,063,728 | +$130,270,111 | $28.51 | 182 |
| 2024 Q2 | 74,718,656 | $1,972,484,501 | +$94,283,095 | $26.40 | 195 |
| 2024 Q1 | 70,316,923 | $2,271,922,665 | +$28,234,974 | $32.31 | 208 |
| 2023 Q4 | 68,405,672 | $2,881,981,571 | +$25,897,847 | $42.13 | 227 |
| 2023 Q3 | 68,143,903 | $2,616,088,544 | +$461,829,770 | $38.39 | 179 |
| 2023 Q2 | 55,460,743 | $1,051,890,599 | -$33,129,073 | $18.97 | 145 |
| 2023 Q1 | 58,264,079 | $903,668,302 | +$20,897,901 | $15.51 | 140 |
| 2022 Q4 | 56,538,511 | $1,003,523,628 | +$261,143,310 | $17.75 | 132 |
| 2022 Q3 | 42,668,627 | $238,077,080 | +$13,851,662 | $5.58 | 107 |
| 2022 Q2 | 40,117,493 | $156,470,492 | +$2,266,222 | $3.90 | 87 |
| 2022 Q1 | 39,493,605 | $217,710,240 | -$1,326,202 | $5.51 | 108 |
| 2021 Q4 | 37,845,291 | $322,423,547 | -$6,093,696 | $8.52 | 118 |
| 2021 Q3 | 33,769,857 | $293,475,463 | -$50,043,046 | $8.69 | 115 |
| 2021 Q2 | 38,555,821 | $407,535,405 | -$67,673,203 | $10.57 | 110 |
| 2021 Q1 | 40,251,421 | $645,603,475 | -$273,082,395 | $16.04 | 118 |
| 2020 Q4 | 40,331,237 | $1,862,979,798 | +$41,257,802 | $46.19 | 146 |
| 2020 Q3 | 39,828,501 | $1,401,617,459 | +$384,378,297 | $35.19 | 116 |
| 2020 Q2 | 28,564,750 | $695,567,285 | +$388,041,409 | $24.35 | 87 |
| 2020 Q1 | 12,628,676 | $193,544,419 | +$19,992,364 | $15.56 | 40 |
| 2019 Q4 | 11,331,532 | $175,598,863 | +$163,278,863 | $15.87 | 24 |